By Finance Pulse in Transformative —

Sanofi Ends Maze Licensing Deal Over FTC Concerns

Sanofi has terminated its global licensing agreement with Maze Therapeutics for Pompe disease treatment, citing issues related to FTC regulations.

A visually appealing image of two divided corporate logos, representing Sanofi and Maze, with a symb
Sanofi Ends Maze Licensing Deal Over FTC Concerns

Sanofi scrapped its global licensing agreement with Maze for the Pompe disease treatment due to FTC issues.

Source